TESA
FDA-approved GHRH analog for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy. In phase 3 trials in ART-treated HIV patients, visceral fat changed by -24 cm2 versus +2 cm2 on placebo at 26 weeks, with no clinically meaningful change in glucose parameters at 26 and 52 weeks.
Regulatory status (as of Sept 2026)
Approved prescription product (Egrifta) for HIV-associated lipodystrophy only. Use for general fat loss or anti-aging is off-label. Not addressed by the April 2026 503A Category 2 removals or the July 2026 PCAC votes.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Tesamorelin is an FDA-approved prescription drug. FDA-approved GHRH analog for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | FDA-approved |
| Dosing | Published research: 2 mg subcutaneously daily details2 mg subcutaneously daily; pooled analysis of two multicenter double-blind placebo-controlled phase 3 trials, 806 ART-treated HIV patients with excess abdominal fat (543 tesamorelin, 263 placebo), 26-week core plus 26-week extensionCommunity-reportedCommunity-reported: 2 mg daily, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a lab-made version of the hormone that tells the pituitary gland to release growth hormone. Synthetic GHRH analog with trans-3-hexenoic acid modification, stimulates natural GH release.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported 2 mg daily (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Tesamorelin | No published PK data found | Subcutaneous injection | FDA-approved |
| CJC-1295 (no DAC) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| CJC-1295 (with DAC) | 6-8 days | Subcutaneous injection | Phase 1 / early human |
| GHRP-2 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| GHRP-6 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Growth Hormone category. View All Growth Hormone Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.